Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following subtypes:~  * Diffuse large cell lymphoma (includes primary mediastinal B-cell lymphoma and T-cell-rich B-cell lymphoma)~ * Prior indolent lymphoma (e.g., follicular center cell lymphoma; marginal zone lymphoma, including extranodal mucosa-associated lymphoid tissue \[MALT\] lymphoma; and lymphoplasmacytoid lymphoma) with transformation to diffuse large B-cell lymphoma at relapse~    * Must be histologically confirmed~   * No transformed lymphoma at diagnosis with subsequent indolent histology without transformation at relapse~ * Peripheral T-cell lymphoma~ * Anaplastic large cell lymphoma~ * Small noncleaved Burkitt-like lymphoma~* T-cell or B-cell lineage confirmed by immunohistochemistry~* Clinically or radiologically documented disease meeting either of the following criteria:~  * Measurable disease, defined as at least 1 bidimensionally measurable site of disease using clinical exam, CT scan, or MRI~    * Lymph nodes must be \> 1.5 cm by physical exam or CT scan~   * Other non-nodal lesions must be ≥ 1.0 cm by physical exam, CT scan, or MRI~   * Bone lesions are not considered measurable~ * Evaluable disease, defined as only nonmeasurable disease, including any of the following:~    * Marrow infiltration~   * Cytology-confirmed ascites or effusions~   * Bony involvement~   * Enlarged liver or spleen~   * Unidimensionally measurable intrathoracic or abdominal masses~* Previously treated with 1, and only 1, chemotherapy regimen including an anthracycline and excluding cisplatin, cytarabine, and gemcitabine~* No uncontrolled CNS involvement by lymphoma~  * No CNS disease at time of relapse~ * CNS disease diagnosed at initial presentation allowed provided a complete response for CNS disease was achieved and maintained~PATIENT CHARACTERISTICS:~Age~* 16 to 65~Performance status~* ECOG 0-3~Life expectancy~* At least 12 weeks~Hematopoietic~* Absolute granulocyte count ≥ 1,000/mm\^3~* Platelet count ≥ 75,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT ≤ 2.5 times ULN (5 times ULN if liver involvement with lymphoma)~* Hepatitis B status known (for patients with a history of hepatitis B or who are at high risk of hepatitis B infection)~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No significant cardiac dysfunction or cardiovascular disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Willing to complete quality of life questionnaires~* HIV negative~* No active, uncontrolled bacterial, fungal, or viral infection~* No other malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~* No other concurrent serious illness or medical condition that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Chemotherapy~* Prior rituximab allowed~Chemotherapy~* See Disease Characteristics~* At least 4 weeks since prior IV chemotherapy~* No prior high-dose chemotherapy with stem cell transplantation~Endocrine therapy~* No concurrent corticosteroids except for physiologic replacement~Radiotherapy~* At least 4 weeks since prior radiotherapy and recovered~  * Exceptions may be made for low-dose, non-myelosuppressive radiotherapy~* No prior radiotherapy to more than 25% of functioning bone marrow~* Involved-field radiotherapy may be given to areas of bulky disease at relapse (≥ 5 cm) after stem cell transplantation, according to the center's policy~Surgery~* At least 2 weeks since prior major surgery~Other~* No other concurrent anticancer therapy~* No other concurrent experimental agents

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Salvage arm I (Type: EXPERIMENTAL): Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
- Salvage arm II (Type: EXPERIMENTAL): Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
- Maintenance arm I (Type: EXPERIMENTAL): Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
- Maintenance arm II (Type: NO_INTERVENTION): Patients undergo observation only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete